CClinicalTrials.gg
CompletedNCT02188004Updated May 7, 2019

The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases

An observational study in Human Papillomavirus Infection and Genital Warts, sponsored by Jun Zhang. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-07.

Sponsored by Jun Zhang · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,691
Ages
18 Years to 55 Years
Sex
All
01

Study summary

primary purpose:Evaluate the prevalence and incidence of HPV infection and related diseases in subjects.

Secondary purpose:Analyze risk factors of HPV infection and related diseases.

02

Conditions studied

  • Human Papillomavirus Infection
  • Genital Warts

Keywords

  • HPV
  • genital warts
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 4,691 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Jun Zhang is the lead sponsor of 21 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

5000 healthy volunteers will be recruited from the residents of Liuzhou through advertisment.

Inclusion criteria

  • ages 18 to 55 years;
  • residents of the study site;
  • at least one sex partner;
  • Be able to understand and comply with the request of the protocol.

Exclusion criteria

Exclusion Criteria:

  • pregnant;
  • has received HPV vaccines.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,691 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. prevalence and incidence of HPV infection

    Evaluate the prevalence and incidence of HPV infection and related diseases in subjects

    Time frame: 1 year

Secondary outcomes

  1. risk factors of HPV infection and related diseases

    Analyze risk factors of HPV infection and related diseases.

    Time frame: 1 year

07

Study locations

1 site
  • Liuzhou Center of disease prevention and control
    Liuzhou, Guangxi, China
08

References and documents

Publications

  • Wei F, Guo M, Huang S, Li M, Cui X, Su Y, Wu X, Ma X, Zheng Y, Huang Y, Wang L, Pan L, Wu T, Zhang J, Xia N. Sex Differences in the Incidence and Clearance of Anogenital Human Papillomavirus Infection in Liuzhou, China: An Observational Cohort Study. Clin Infect Dis. 2020 Jan 1;70(1):82-89. doi: 10.1093/cid/ciz168. PubMed 30852604 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02188004
Lead sponsor
Jun Zhang
Collaborators
Liuzhou center of disease prevention and control
Responsible party
Jun Zhang (professor, Xiamen University) — Sponsor-investigator
First posted
Jul 11, 2014
Start date
Jun 2014
Primary completion
May 2016
Completion
May 2016
Last update
May 7, 2019

Study contacts

Jun Zhang
study chair · Xiamen University
Ming-Qiang Li
principal investigator · Liuzhou center of disease prevention and control

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion